Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Understanding in Depth the Physical Inactivity of Patients With COPD: Comparison of the Summer-Winter Variability in the Level of Physical Activity in Daily Life in Brazilian and Belgian Patients
Up to this moment, the majority of studies assessing the level of physical activity in daily
life in patients with COPD are limited to a cross-sectional design, which does not take into
account natural variation of physical activity in daily life due to differences in climatic
conditions faced throughout the year. Preliminary evidences suggest that patients with COPD
have different physical activity levels according to the seasons of the year. However, the
limited current evidences do not allow us to know the magnitude of differences in the level
of daily physical activity in patients with COPD when taking into account climatic changes
resulting from different seasons of the year in cities and countries with contrasting
climatic conditions. This gap observed in the literature does not allow us at this moment to
know whether we should or not consider the season of the year as one of the main causes of
variability while assessing physical activity in daily life in patients with COPD.
The present project proposes to investigate the hypothesis that patients with COPD who live
in a place with less marked decrease in temperature between summer and winter (Londrina,
Brazil) have less variability in the level of physical activity in daily life through the
year in comparison to patients who live in a place with more marked climatic variability
during these seasons (Leuven, Belgium).
| Status | Recruiting |
| Enrollment | 40 |
| Est. completion date | November 2015 |
| Est. primary completion date | August 2015 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Diagnosis of COPD based on internationally accepted criteria - Clinical stability (absence of exacerbations) for at least 3 months before inclusion in the study - Absence of orthopedic comorbidities which could interfere on the performance of the proposed assessments Exclusion Criteria: - Patients will be excluded of the study if they do not demonstrate physical or cognitive conditions to complete the proposed assessments, - If they suffer from a moderate or severe acute exacerbation in the period between the two assessment points - If they decide to leave the study for any reason |
Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| Belgium | University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium | Leuven | |
| Brazil | University Hospital Londrina , Universidade Estadual de Londrina, Brasil | Londrina | Paraná |
| Lead Sponsor | Collaborator |
|---|---|
| Universidade Estadual de Londrina | Katholieke Universiteit Leuven |
Belgium, Brazil,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Physical activity in daily life | Two activity monitors (the SenseWear armband and the Fitbit) will be simultaneously worn during 7 consecutive days. The SenseWear armband (BodyMedia, Pittsburg, PA, USA) is a multisensor composed by a biaxial accelerometer and physiologic sensors. It is a small (8.8 x 5.6 x 2 cm) and lightweight (82g) monitor that was already validated for energy expenditure estimation in patients with COPD. The Fitbit (Fitbit, Inc., San Francisco, CA, USA) is a recently released triaxial accelerometer that is smaller (3.6 x 2.9 x 1 cm) and more lightweight (8g) than the SenseWear. This device provides the number of steps, the distance walked and the energy expenditure in calories, among other variables. In the 7 days of assessment, the patient will remain with the device during 24 hours/day. The patients will be strictly instructed to avoid changing their daily physical activity habits during the monitoring period. | January 2013 and July 2013. Participants will be followed for the duration of 6 months. | No |
| Secondary | Six minute walking test | Two tests will be performed with 30 minutes of interval, according to international standards. Subjects will be encouraged to walk during 6 minutes as fast as possible in a straight leveled 30-meter corridor. Reference values will be those by Troosters et al. | January 2013 and July 2013. Participants will be followed for the duration of 6 months. | No |
| Secondary | Spirometry | Pulmonary function test (post-bronchodilator spirometry) measuring slow vital capacity (SVC), forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio will be performed by the use of a hand-held spirometer (Spiropalm, Cosmed, Italy), following the American Thoracic Society - European Respiratory Society (ATS-ERS) standardized protocol [14] and based on the reference values by Pereira et al. for Brazilian patients and Knudson et al. for European patients. | January 2013 and July 2013. Participants will be followed for the duration of 6 months. | No |
| Secondary | Chronic Respiratory Disease Questionnaire (CRQ) | The CRQ contains 20 questions divided in 4 domains: dyspnea (5 questions), fatigue (4 questions), emotional function (7 questions) and self control (4 questions). The dyspnea domain is individualized, which means that each patient selects from a list the activities which induce dyspnea in the last two weeks, and they can report other activities that are not on the list. Subsequently, among the reported and selected activities, the patient chooses 5 activities considered the most important ones and by the use of a scale of 7 points the patient grades how much dyspnea interferes on these activities. In this scale the score ranges from 1 (maximum impairment) to 7 (no impairment at all). Concerning the other domains (fatigue, emotional function and self control), the questions are standardized and the patient answers each question using the scale of 7 points. The results are presented on average score of each domain, and the higher the score, the better the subject quality of life. | January 2013 and July 2013. Participants will be followed for the duration of 6 months. | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
| Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
| Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
| Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
| Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
| Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
| Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
| Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
| Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
| Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
| Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
| Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
| Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
| Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
| Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
| Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|